Pharmacy

 

Preparing for the 2025 healthcare investment landscape — in conversation with Sharon Lamb, Partner at McDermott, Will & Emery

As the healthcare and life sciences sector emerges from a period of consolidation and slower deal activity, investors are eyeing 2025 with cautious optimism. HPE Europe, a conference hosted by multinational law firm McDermott, Will & Emery (MWE), convened in London this autumn to explore key investment themes and strategies for the year ahead, with HBI in attendance.
October 31, 2024

Sanofi and CD&R enter exclusive agreement for Opella sale, and promise to keep jobs in France

French pharma giant Sanofi and US PE firm Clayton Dubilier & Rice (CD&R) have been made to sign a promise to the French government to keep factories and jobs in France after the sale of a 50% stake in Sanofi's consumer health division, Opella, to CD&R. Sanofi and CD&R are now in exclusive talks for the sale, in a deal which is valuing Opella at $16.4 billion.
October 25, 2024

Sanofi deal row a “non-event” indicating French politicians’ “lack of maturity in handling cross-border M&A deals”

On October 11, Reuters reported that Sanofi, the French drugmaker, is negotiating a sale of a 50% stake in its consumer health business, Opella, to US private equity firm Clayton Dubilier & Rice (CD&R). The negotiation is valuing the business at €16.4 billion. This move is part of Sanofi's strategy to separate its consumer healthcare segment to fund new drug development.
October 18, 2024

UK launches £400 million public-private partnership to address critical need in pharmaceutical testing

The UK’s Department of Health and Social Care (DHSC), NHS England, and the Association of the British Pharmaceutical Industry (ABPI) have launched a £400 million initiative to improve the country’s pharmaceutical testing capabilities. Termed the ‘Voluntary Scheme for Branded Medicine Pricing, Access and Growth’ (VPAG), this public-private investment will create up to 18 new clinical trial hubs across the UK, speeding up the development and availability of new medicines, as detailed in the August 28 press release.
August 29, 2024

Germany’s pharmaceutical company STADA expands its presence in MENA region

STADA, a European pharmaceutical company based in Germany, has acquired the FITO™ trademark from Leo Pharma, a multinational Danish pharmaceutical company, to expand its consumer healthcare presence in the Middle East and North Africa (MENA) region.  International law firm Bird & Bird has advised STADA Group on acquiring the FITO business from Leo Pharma in an asset deal.
August 16, 2024

Healthcare investment “through the bottom of the cycle” — Goldberg (Rothschild)

At last year’s conference Hedley Goldberg, Managing Director at multinational investment bank Rothschild, predicted healthcare M&A activity would begin picking up again in Q4 2023 or Q1 2024. But we’re now halfway through 2024 and there are still very few deals above €500m taking place. Goldberg is confident, however, that we have now passed through the bottom of the cycle.
June 20, 2024

HBI News Round Up, 7th June 2024

In this HBI News Round Up, we look at the recent UK cyberattack that disrupted healthcare services at hospitals and GP clinics, Sweden's 'Care Recovery Plan', the plans for the Swedish island of Gotland propose the region become a pilot area for state intervention and Australia's five-year deal with pharmacists. 
June 7, 2024

Italy’s pharmacies to offer expanded range of services

A new draft bill has been proposed by the Italian government which will allow pharmacies to offer an expanded range of services including vaccinations, diagnostic tests and the ability to book outpatient visits to the hospital. 
March 22, 2024

UK pharmacists given green light to prescribe as primary care can’t cope

Pharmacists in the UK now have the right to prescribe for common ailments such as sore throats and earaches. In France, Ireland and Portugal pharmacists also have some prescribing rights and similar initiatives may be introduced in other European countries in the near future. Is this a solution to the GP workforce shortage? And will it be a good thing for private hospital and private primary care groups?
February 2, 2024
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us